Pharmacist-Guided Benzodiazepine Deprescribing in Older Adults
Benzodiazepines remain common in Australian prescribing, particularly for anxiety and sleep problems in older adults. Many people have taken them for years, often alongside antidepressants, opioids, antihistamines or alcohol. A medication review may show that the original indication has faded, the dose has crept upward, or the risks now outweigh the benefits.
Older adults are more susceptible to sedation, impaired coordination and confusion. Benzodiazepines can increase the risk of falls, fractures, delirium and road crashes, with the Therapeutic Goods Administration warning about these harms even when medicines are used as prescribed. Stopping suddenly also carries risks: withdrawal can cause anxiety, insomnia, agitation and, in severe cases, seizures.
This framework places the pharmacist at the centre of a shared-care process: identify who is prescribing, clarify what the medicine is for, assess dependence and withdrawal risk, negotiate a gradual plan and monitor the person after each change. The prescriber remains responsible for medication orders, while Australian law, professional scope and clinical judgement guide the process.
Why a structured reduction matters
Deprescribing is the planned reduction or discontinuation of a medicine when its benefits no longer outweigh its harms. It is not simply removing a tablet from the repeat list. A safe process explains the reasons for change, involves the older adult in decisions, adjusts the pace according to withdrawal symptoms and maintains support when difficulties appear.
A structured approach also protects against two common errors: leaving an unnecessarily high dose unchanged because nobody owns the review, or reducing too quickly because the medication appears straightforward. Falls, cognitive changes and hospital admissions often have several causes. Benzodiazepines may contribute, but pain, infection, dehydration, orthostatic hypotension and changes in vision or medication can also need attention.
Prescribing rules differ across states and territories. Alprazolam, for example, is a Schedule 8 medicine in New South Wales and Queensland, and supply requirements differ for other benzodiazepines. Pharmacists should check current local requirements rather than assuming a national standard. The RACGP’s Be Clear Change resources and Australian deprescribing guidance provide useful clinical frameworks for this work.
Assess exposure, dependence and priorities
Start with a complete medication history. Reconcile the dispensing record, the person’s own medicines and the medicines held by family or carers. Ask which GPs, specialists, hospitals and pharmacies have been involved, and obtain recent discharge summaries or residential aged-care medication charts where relevant. Repeated early repeats, lost medicines or prescriptions from several prescribers can reveal fragmented care.
Assess why the benzodiazepine is being used and whether that need still exists. Screen for depression, post-traumatic stress, panic, problematic alcohol use, pain, nocturia and sleep apnoea. Ask about dose escalation, morning use, missed doses followed by tremor or anxiety, craving, and use despite falls or cognitive problems. A recognised withdrawal assessment tool can support this process, alongside observations of sedation, balance and cognition.
Because benzodiazepines are generally not listed on the Pharmaceutical Benefits Scheme, cost may affect whether someone fills every repeat or keeps an older supply for tapering. Discuss affordability privately and without judgement. Ask what good sleep and calmer days mean to the patient, and what they value: fewer falls, less fogginess, better confidence or more independence. Use plain language and interpreters where needed. Offer Aboriginal and Torres Strait Islander health workers when wanted, and work with local Aboriginal community-controlled health services where relevant.
Build a shared, gradual reduction plan
Present the balance of benefits and harms without blame, then offer choices. Options include reducing the current medicine, changing to a different preparation, continuing at a lower stable dose with monitoring, or seeking specialist input. A broader health-sector perspective from Johnathan Laird can complement local clinical resources, but the plan itself should be built with the person receiving care.
A reduction of approximately 5–10% of the current dose every two to four weeks is a commonly used starting range. It is not a universal schedule or a substitute for individual assessment. Some people need smaller reductions, longer intervals or pauses, particularly after long-term use, while others tolerate a slower pace poorly because of severe anxiety or insomnia. The prescriber should specify the schedule and review dates in a shared plan.
Do not abruptly discontinue regular long-term use. Sudden cessation can produce severe withdrawal, including seizures and delirium. Where urgent concerns such as profound sedation require faster intervention, the treating team should supervise the change. Switching to a longer-acting benzodiazepine can sometimes smooth withdrawal, but the prescriber must calculate any equivalent dose carefully and change only one medicine at a time. Give the patient a written schedule, a symptom diary and a named contact for questions.
Support withdrawal and coordinate care
Withdrawal is not a test of the patient’s commitment. Acknowledge anxiety and disturbed sleep, and distinguish temporary adjustment from signs that the reduction is too fast. For insomnia, consider referral for cognitive behavioural therapy for insomnia and investigate problems requiring separate treatment, such as sleep apnoea, pain, nocturia or depression. Where eligible, a GP can arrange a Medicare-subsidised psychology pathway that includes this treatment.
Coordinate with the GP and, where appropriate, request a Home Medicines Review. In residential aged care, the supplying pharmacist, facility pharmacist, authorised prescriber and GP may each hold important information. In regional New South Wales or northern Queensland, telehealth can connect community pharmacists with medical clinicians, although travel distance, broadband access and local pharmacy coverage still determine what is feasible. Document responsibilities clearly so that a patient does not receive conflicting advice.
Urgent warning signs include new confusion or hallucinations, seizures, severe agitation, repeated vomiting, suicidal thoughts, or oversedation that makes waking or breathing difficult. For immediate danger, call 000 or attend an emergency department. For non-emergency advice, healthdirect’s nurse line on 1800 022 222 can help identify appropriate local care.
A repeatable checklist for sustained reduction
Clear written instructions help patients remember what happens next. The blog post checklist illustrates how a simple structure can make communication consistent; adapt that discipline to clinical documentation without treating it as a prescribing protocol.
Before starting:
- Confirm the medicine, dose, timing, prescriber and current indication.
- Review recent falls, confusion, hospital admissions and sedative combinations.
- Ask about tolerance, withdrawal symptoms, alcohol use and affordability.
- Record the patient’s goals, consent and the first review date.
At each review:
- Ask about sleep, anxiety, cognition, balance and withdrawal symptoms.
- Check the dispensing record for additional supplies or prescribers.
- Adjust the reduction pace with the prescriber when needed.
- Communicate changes to the patient, GP and aged-care team.
Use these prompts as a safety net, then tailor them to the person’s health, preferences and support network.
Matching the pathway to clinical need and available support helps avoid unnecessary escalation or an unsupported home taper.
| Feature | Community pharmacy pathway | Primary care-supported pathway | Specialist or hospital pathway |
|---|---|---|---|
| Main lead | Pharmacist, with prescriber approval | Prescriber-led plan with pharmacist follow-up | Clinician or specialist with close monitoring |
| Best suited to | Stable health, modest withdrawal risk and good community support | Multiple medicines, frailty or several prescribers | Severe withdrawal, unstable illness or complex comorbidity |
| Review pattern | Pharmacist contact every one to two weeks initially, then as agreed | Review alongside GP appointments and after each dose change | Frequent clinical review or inpatient observation, depending on severity |
| Key safeguards | Shared notes, medication reconciliation and prompt escalation | Clear allocation of responsibilities across the care team | Supervised prescribing, close monitoring and immediate access to treatment |
Make the next step concrete. Select one older adult whose benzodiazepine use warrants review, arrange a private pharmacist appointment and obtain the prescriber’s agreement to a shared plan. Record the indication, current dose, proposed reduction, review date and escalation contacts, then make the first follow-up appointment before the patient leaves the pharmacy. Repeat the process with the next patient until benzodiazepine review becomes routine care rather than an exceptional event.